Wenbing Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenbing Liu has a total of 79 co-authors. Here are the top co-authors by number of shared publications:
- Jianxiang Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
9 shared publications - Shaowei Qiu
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
6 shared publications - Hui Wei
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
5 shared publications Min Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
5 shared publications- Ying Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
5 shared publications Leling Xie
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China
4 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72395
Transcriptome Analysis Identifies a Myeloid‐Like Signature in Relapsed or Refractory B ‐Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy
Background: Relapsed or refractory B‐cell acute lymphoblastic leukemia (R/R B‐ALL) patients exhibit heterogeneous responses to CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy. However, current studies primarily focus on the CAR‐T cells or the leukemia blasts, and the patient's intrinsic molecular characteristics before treatment remain poorly understood. Methods: Fifteen R/R B‐ALL patients enrolled in a phase II, single‐arm clinical trial (NCT04684147) were stratified at a three‐month landmark into 8 good responders and 7 poor responders. Clinical characteristics, genetic alterations and pre‐treatment bone marrow transcriptomics were compared between groups, and an exploratory gene‐expression score was derived. Results: Differential expression and enrichment analyses identified a myeloid‐like signature and upregulation of myeloid‐related genes in poor responders. Seven myeloid‐related genes were examined in independent patient cohorts, in B‐ALL cell lines and at single‐cell resolution in one patient; three were expressed by the leukemic cells themselves and four predominantly by monocytes and macrophages. A separate, variance‐derived seven‐gene least absolute shrinkage and selection operator (LASSO) score separated response groups in the discovery cohort (apparent area under the curve, AUC 1.00), with bias‐corrected and external estimates of approximately 0.57–0.59 (external cohort AUC 0.592, 95% confidence interval 0.356–0.828). Conclusions: Pre‐treatment transcriptomic profiling revealed a myeloid‐like signature in R/R B‐ALL patients with poor CD19 CAR‐T response, warranting further investigation as a candidate correlate of treatment outcome.
- 19 October 2026
- Published by Wiley in Cancer Medicine
- Vol. 15 (10) , e72395
Open AccessTranscriptome Analysis Identifies a Myeloid‐Like Signature in Relapsed or Refractory B ‐Cell Acute Lymphoblastic Leukemia Patients With Poor Response to CD19 Chimeric Antigen Receptor T Cell Therapy
Background: Relapsed or refractory B‐cell acute lymphoblastic leukemia (R/R B‐ALL) patients exhibit heterogeneous responses to CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy. However, current studies primarily focus on the CAR‐T cells or the leukemia blasts, and the patient's intrinsic molecular characteristics before treatment remain poorly understood. Methods: Fifteen R/R B‐ALL patients enrolled in a phase II, single‐arm clinical trial (NCT04684147) were stratified at a three‐month landmark into 8 good responders and 7 poor responders. Clinical characteristics, genetic alterations and pre‐treatment bone marrow transcriptomics were compared between groups, and an exploratory gene‐expression score was derived. Results: Differential expression and enrichment analyses identified a myeloid‐like signature and upregulation of myeloid‐related genes in poor responders. Seven myeloid‐related genes were examined in independent patient cohorts, in B‐ALL cell lines and at single‐cell resolution in one patient; three were expressed by the leukemic cells themselves and four predominantly by monocytes and macrophages. A separate, variance‐derived seven‐gene least absolute shrinkage and selection operator (LASSO) score separated response groups in the discovery cohort (apparent area under the curve, AUC 1.00), with bias‐corrected and external estimates of approximately 0.57–0.59 (external cohort AUC 0.592, 95% confidence interval 0.356–0.828). Conclusions: Pre‐treatment transcriptomic profiling revealed a myeloid‐like signature in R/R B‐ALL patients with poor CD19 CAR‐T response, warranting further investigation as a candidate correlate of treatment outcome.
- Open Access
- 29 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8136) , E5
Author Correction: Proteasome-guided haem signalling axis contributes to T cell exhaustion
- 29 September 2026
- Published by Springer Nature in Nature
- Vol. 658 (8136) , E5
Open AccessAuthor Correction: Proteasome-guided haem signalling axis contributes to T cell exhaustion
- Open Access
- 7 September 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Development and validation of a five-gene palmitoylation-associated prognostic model in acute myeloid leukemia
- 7 September 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessDevelopment and validation of a five-gene palmitoylation-associated prognostic model in acute myeloid leukemia
- 7 May 2026
- Published by Springer Nature in Nature
- Vol. 653 (8115) , E11
Author Correction: Proteasome-guided haem signalling axis contributes to T cell exhaustion
- 7 May 2026
- Published by Springer Nature in Nature
- Vol. 653 (8115) , E11
Author Correction: Proteasome-guided haem signalling axis contributes to T cell exhaustion
- Top Cited PapersOpen Access
- 18 March 2026
- Published by Springer Nature in Nature
- Vol. 653 (8114) , 548-557
Proteasome-guided haem signalling axis contributes to T cell exhaustion
The accumulation of depolarized mitochondria commits T cells to exhaustion 1–3 , yet the precise mechanism remains unclear. Here we find that exhausted CD8 + T cells increase proteasome activity owing to the accumulation of depolarized mitochondria, which drives the selective degradation of mitochondrial proteins and the release of regulatory haem through haemoprotein breakdown. In turn, increased regulatory haem disrupts BACH2-mediated transcriptional regulation, thereby exacerbating T cell exhaustion and compromising stemness-like properties. Inhibition of nuclear import of regulatory haem prevents BACH2 degradation and enhances the anti-tumour efficacy of antigen-specific T cells. We find that the therapeutic efficacy of human CD19 + chimeric antigen receptor (CAR)-T cells in patients with B cell acute lymphoblastic leukaemia negatively correlates with the proteasome gene signature in their CAR-T cells. Manufacturing CAR-T cells in the presence of bortezomib, an FDA-approved proteasome inhibitor, prevents T cell exhaustion and improves therapeutic efficacy. Our findings identify a proteasome-guided haem signalling axis, governed by mitochondrial integrity, as a regulator of CD8 + T cell exhaustion and propose innovative therapeutic strategies that exploit this pathway to optimize adoptive cellular immunotherapy.
- 18 March 2026
- Published by Springer Nature in Nature
- Vol. 653 (8114) , 548-557
Top Cited PapersOpen AccessProteasome-guided haem signalling axis contributes to T cell exhaustion
The accumulation of depolarized mitochondria commits T cells to exhaustion 1–3 , yet the precise mechanism remains unclear. Here we find that exhausted CD8 + T cells increase proteasome activity owing to the accumulation of depolarized mitochondria, which drives the selective degradation of mitochondrial proteins and the release of regulatory haem through haemoprotein breakdown. In turn, increased regulatory haem disrupts BACH2-mediated transcriptional regulation, thereby exacerbating T cell exhaustion and compromising stemness-like properties. Inhibition of nuclear import of regulatory haem prevents BACH2 degradation and enhances the anti-tumour efficacy of antigen-specific T cells. We find that the therapeutic efficacy of human CD19 + chimeric antigen receptor (CAR)-T cells in patients with B cell acute lymphoblastic leukaemia negatively correlates with the proteasome gene signature in their CAR-T cells. Manufacturing CAR-T cells in the presence of bortezomib, an FDA-approved proteasome inhibitor, prevents T cell exhaustion and improves therapeutic efficacy. Our findings identify a proteasome-guided haem signalling axis, governed by mitochondrial integrity, as a regulator of CD8 + T cell exhaustion and propose innovative therapeutic strategies that exploit this pathway to optimize adoptive cellular immunotherapy.
- Open Access
- 12 February 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (6) , 2164-2170
Single-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia
- 12 February 2026
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 111 (6) , 2164-2170
Open AccessSingle-cell dissection of plasma cell clonal evolution to smoldering multiple myeloma after CD19 CAR-T cell therapy in B-cell acute lymphoblastic leukemia
- Open Access
- 5 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (10) , 2573
Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
- 5 September 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (10) , 2573
Open AccessCorrection: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
- 30 June 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (8) , 1838-1847
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
Tyrosine kinase inhibitors (TKIs) combined with chemotherapy and immunotherapy evolved as the standard treatment for newly diagnosed (ND) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nonetheless, the efficacy and safety of combining TKIs with BCL-2 inhibitors in ND Ph+ ALL have yet to be fully elucidated. Hence, we carried out a prospective clinical trial to explore the efficacy and safety of olverembatinib combined with venetoclax and reduced-intensity chemotherapy as frontline treatment in Ph+ ALL. From October 2022 to March 2024, a total of 79 patients with a median age of 42 years completed a minimum of three cycles of olverembatinib and venetoclax-based regimen. The primary end point of the study was the complete molecular response (CMR) rate at 3 months. Ultimately, the regimen achieved CMR of 62.0% at 3 months in the absence of intensive chemotherapy or immunotherapy. No deaths occurred during the induction phase. With a median follow-up of 12 months, the estimated 1-year overall survival (OS) and event-free survival (EFS) rates were 93.1% (95% CI 86.4–99.8) and 89.1% (95% CI 80.3–97.9), respectively. Transcriptomic data revealed a potential complementary mechanism between TKIs and venetoclax, thereby verifying the rationale for the combination of these two agents. In conclusion, our study provides an alternative treatment strategy for patients with ND Ph+ ALL, particularly for those who are unfit or unavailable for immunotherapy or intensive chemotherapy at the initial stage of treatment. Clinical trial registration: The study was registered at https://clinicaltrials.gov/ with the registration number of NCT05594784.
- 30 June 2025
- Published by Springer Nature in Leukemia
- Vol. 39 (8) , 1838-1847
Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial
Tyrosine kinase inhibitors (TKIs) combined with chemotherapy and immunotherapy evolved as the standard treatment for newly diagnosed (ND) Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Nonetheless, the efficacy and safety of combining TKIs with BCL-2 inhibitors in ND Ph+ ALL have yet to be fully elucidated. Hence, we carried out a prospective clinical trial to explore the efficacy and safety of olverembatinib combined with venetoclax and reduced-intensity chemotherapy as frontline treatment in Ph+ ALL. From October 2022 to March 2024, a total of 79 patients with a median age of 42 years completed a minimum of three cycles of olverembatinib and venetoclax-based regimen. The primary end point of the study was the complete molecular response (CMR) rate at 3 months. Ultimately, the regimen achieved CMR of 62.0% at 3 months in the absence of intensive chemotherapy or immunotherapy. No deaths occurred during the induction phase. With a median follow-up of 12 months, the estimated 1-year overall survival (OS) and event-free survival (EFS) rates were 93.1% (95% CI 86.4–99.8) and 89.1% (95% CI 80.3–97.9), respectively. Transcriptomic data revealed a potential complementary mechanism between TKIs and venetoclax, thereby verifying the rationale for the combination of these two agents. In conclusion, our study provides an alternative treatment strategy for patients with ND Ph+ ALL, particularly for those who are unfit or unavailable for immunotherapy or intensive chemotherapy at the initial stage of treatment. Clinical trial registration: The study was registered at https://clinicaltrials.gov/ with the registration number of NCT05594784.
- 31 October 2024
- Published by Springer Nature in Leukemia
- Vol. 39 (1) , 238-242
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
- 31 October 2024
- Published by Springer Nature in Leukemia
- Vol. 39 (1) , 238-242
The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patients
- Open Access
- 16 September 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 162
Multiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia
- 16 September 2024
- Published by Springer Nature in Blood Cancer Journal
- Vol. 14 (1) , 162
Open AccessMultiomic analysis identifies a high-risk subgroup that predicts poor prognosis in t(8;21) acute myeloid leukemia